Did you know that you can optimise your noise-cancellation settings? Noise-cancellation technology allows users to tweak settings by running an analysis of new and different conditions. The optimise ...

1 Leggy black nightstands with a small drawer for function contrast the wallpaper and set off the trim on the lampshades and art frames. The sensuously curved double sconces are from Lulu and Georgia.

There are also aesthetic upgrades across the board. Apple has added new Unity Rhythm wallpapers, as well as interactive watch faces for the Apple Watch. These wallpapers move once you unlock your ...

“Frictionless” is one of those tech-world ideals that sounds more promising than it actually is. What if you could press a button and get all the music in the world? And what if that music ...

“No other decorative device or object can accomplish so much per dollar as wallpaper.” That’s the midcentury decorator Michael Greer, writing in his gem of a book “Inside Design ...

They show that he plans to divest stock holdings, including stakes in biotech firms CRISPR Therapeutics AG and Dragonfly Therapeutics. He’s also stepping down from roles at his law firm and at ...

A requisite majority of H-class shareholders did not approve the buyout, the companies said. "The proposed privatisation of the Company (Henlius) will not proceed and the listing of the H Shares ...

Primarily, Ascentage hopes to leverage the IPO proceeds to advance its pipeline. Around $50 million to $60 million, for instance, will help the biotech pursue approval for its BCL-2 blocker ...

The biotech firm's mRNA-1018 candidate posted positive results in a Phase 1/2 study launched in 2023. Moderna plans to move mRNA-1018 to a Phase 3 trial. Shares of Moderna (MRNA) took off Tuesday ...

In 2019, Stan­ford Uni­ver­si­ty pro­fes­sor Irv Weiss­man and a col­league pub­lished a pa­per that rep­re­sent­ed a new way to tar­get some ag­gres­sive can­cers.

Odyssey Therapeutics and Sionna Therapeutics have filed IPO paperwork, swelling the pack of startups that will provide an early look at how receptive public investors could be to biotech listings ...